Ken Griffin Fibrogen Inc Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$0.33 - $1.26 $24,618 - $93,996	-74,600 Reduced 68.38%	34,500 $13,000
Q2 2024 Aug 14, 2024	BUY	$0.89 - $2.36 $29,014 - $76,936	32,600 Added 42.61%	109,100 $97,000
Q1 2024 May 15, 2024	BUY	$0.73 - $2.73 $42,778 - $159,978	58,600 Added 327.37%	76,500 $179,000
Q4 2023 Feb 14, 2024	BUY	$0.38 - $0.91 $4,408 - $10,556	11,600 Added 184.13%	17,900 $15,000
Q3 2023 Nov 14, 2023	SELL	$0.79 - $2.83 $300,990 - $1.08 Million	-381,000 Reduced 98.37%	6,300 $5,000
Q2 2023 Aug 14, 2023	BUY	$2.49 - $20.59 $851,829 - $7.04 Million	342,100 Added 756.86%	387,300 $1.05 Million
Q1 2023 May 15, 2023	SELL	$15.95 - $25.18 $126,005 - $198,922	-7,900 Reduced 14.88%	45,200 $843,000
Q4 2022 Feb 14, 2023	BUY	$13.27 - $17.73 $396,773 - $530,127	29,900 Added 128.88%	53,100 $850,000
Q3 2022 Nov 14, 2022	SELL	$11.4 - $14.6 $110,580 - $141,620	-9,700 Reduced 29.48%	23,200 $302,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.